Incyte posts 24-week TRuE-AD4 data on long-term safety of ruxolitinib cream in moderate atopic dermatitis at EADV 2026

By Public Technologies
  • Incyte flagged new clinical and real-world data across its inflammation and autoimmunity portfolio for presentation at EADV 2026 in Vienna.
  • Key readouts center on ruxolitinib cream in moderate atopic dermatitis, including longer-term safety, patient-reported benefits, and reduced need to escalate therapy.
  • Povorcitinib Phase 3 analyses in hidradenitis suppurativa highlight improvements across clinical outcomes, patient-reported burden, and biomarkers in higher-burden patients.
  • Additional studies outline market and utilization dynamics in prurigo nodularis, including prevalence, treatment patterns, and healthcare resource use in the US and Germany.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220830BIZWIRE_USPR_____20260922_BW373347) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.